Cargando…

The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial

PURPOSE: The mainstay of therapy for coagulation factor deficiency in cardiac surgical patients is frozen plasma (FP); however, prothrombin complex concentrates (PCCs) may offer logistical and safety advantages. As there is limited comparative evidence, we conducted this study to explore the associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartoszko, Justyna, Callum, Jeannie, Karkouti, Keyvan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563600/
https://www.ncbi.nlm.nih.gov/pubmed/34523108
http://dx.doi.org/10.1007/s12630-021-02100-4
_version_ 1784593438362042368
author Bartoszko, Justyna
Callum, Jeannie
Karkouti, Keyvan
author_facet Bartoszko, Justyna
Callum, Jeannie
Karkouti, Keyvan
author_sort Bartoszko, Justyna
collection PubMed
description PURPOSE: The mainstay of therapy for coagulation factor deficiency in cardiac surgical patients is frozen plasma (FP); however, prothrombin complex concentrates (PCCs) may offer logistical and safety advantages. As there is limited comparative evidence, we conducted this study to explore the association of comparable PCC or FP doses with transfusion and outcomes. METHODS: This was a post hoc analysis of a multicentre randomized trial comparing fibrinogen concentrate with cryoprecipitate (FIBRES trial) in bleeding cardiac surgical patients. This analysis included 415 patients who received only PCC (n = 72; 17%) or only FP (n = 343; 83%) for factor replacement. The main outcomes of interest were red blood cell (RBC) and platelet transfusion within 24 hr of cardiopulmonary bypass. Secondary outcomes included postoperative adverse events. Associations were examined by hierarchical generalized estimating equation models adjusted for demographic and surgical characteristics. RESULTS: The median [interquartile range (IQR)] PCC dose was 1,000 [1,000–2,000] units, while the median [IQR] FP dose was 4 [2–6] units. Each unit of FP was independently associated with increased adjusted odds of RBC (1.60; 95% confidence interval [CI], 1.36 to 1.87; P < 0.01) and platelet transfusion (1.40; 95% CI, 1.15 to 1.69; P < 0.01) while each 500 units of PCC was independently associated with reduced adjusted odds of RBC (0.67; 95% CI, 0.50 to 0.90; P < 0.01) and platelet transfusion (0.80; 95% CI, 0.70 to 0.92; P < 0.01). Adverse event rates were comparable. CONCLUSIONS: In cardiac surgical patients with post-cardiopulmonary bypass bleeding, PCC use was associated with lower RBC and platelet transfusion than FP use was. Prospective, randomized clinical trials comparing FP with PCC in this setting are warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12630-021-02100-4.
format Online
Article
Text
id pubmed-8563600
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-85636002021-11-04 The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial Bartoszko, Justyna Callum, Jeannie Karkouti, Keyvan Can J Anaesth Reports of Original Investigations PURPOSE: The mainstay of therapy for coagulation factor deficiency in cardiac surgical patients is frozen plasma (FP); however, prothrombin complex concentrates (PCCs) may offer logistical and safety advantages. As there is limited comparative evidence, we conducted this study to explore the association of comparable PCC or FP doses with transfusion and outcomes. METHODS: This was a post hoc analysis of a multicentre randomized trial comparing fibrinogen concentrate with cryoprecipitate (FIBRES trial) in bleeding cardiac surgical patients. This analysis included 415 patients who received only PCC (n = 72; 17%) or only FP (n = 343; 83%) for factor replacement. The main outcomes of interest were red blood cell (RBC) and platelet transfusion within 24 hr of cardiopulmonary bypass. Secondary outcomes included postoperative adverse events. Associations were examined by hierarchical generalized estimating equation models adjusted for demographic and surgical characteristics. RESULTS: The median [interquartile range (IQR)] PCC dose was 1,000 [1,000–2,000] units, while the median [IQR] FP dose was 4 [2–6] units. Each unit of FP was independently associated with increased adjusted odds of RBC (1.60; 95% confidence interval [CI], 1.36 to 1.87; P < 0.01) and platelet transfusion (1.40; 95% CI, 1.15 to 1.69; P < 0.01) while each 500 units of PCC was independently associated with reduced adjusted odds of RBC (0.67; 95% CI, 0.50 to 0.90; P < 0.01) and platelet transfusion (0.80; 95% CI, 0.70 to 0.92; P < 0.01). Adverse event rates were comparable. CONCLUSIONS: In cardiac surgical patients with post-cardiopulmonary bypass bleeding, PCC use was associated with lower RBC and platelet transfusion than FP use was. Prospective, randomized clinical trials comparing FP with PCC in this setting are warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12630-021-02100-4. Springer International Publishing 2021-09-14 2021 /pmc/articles/PMC8563600/ /pubmed/34523108 http://dx.doi.org/10.1007/s12630-021-02100-4 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Reports of Original Investigations
Bartoszko, Justyna
Callum, Jeannie
Karkouti, Keyvan
The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial
title The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial
title_full The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial
title_fullStr The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial
title_full_unstemmed The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial
title_short The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial
title_sort association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the fibres randomized controlled trial
topic Reports of Original Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563600/
https://www.ncbi.nlm.nih.gov/pubmed/34523108
http://dx.doi.org/10.1007/s12630-021-02100-4
work_keys_str_mv AT bartoszkojustyna theassociationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial
AT callumjeannie theassociationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial
AT karkoutikeyvan theassociationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial
AT theassociationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial
AT bartoszkojustyna associationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial
AT callumjeannie associationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial
AT karkoutikeyvan associationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial
AT associationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial